Recent studies of the next generation androgen receptor signalling inhibitors (ARIs) provide exciting data regarding potential future treatment options for metastatic hormone sensitive prostate cancer (mHSPC) patients. This e-learning reviews the data from recent trials and considers the quality of life and cost considerations of such treatments. The course also considers the benefit of these therapies being added to existing treatment with docetaxel and ADT.